Herpes Zoster Treatment Market Size- By Route Of Administration, By Treatment Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Description

Global Herpes Zoster Treatment Market Overview:

According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 0.32 billion by 2032 with a CAGR of 3.68%.

The varicella-zoster virus is the cause of the viral illness known as herpes zoster (shingles). It often starts as a burning, itchy skin rash that spreads to the rest of the body, causing blisters on the back, chest, and face. Pain along the afflicted dermatome is usually the first symptom, which is followed in 2-3 days by an expanded vesicular eruption. Lymph nodes, fever, chills, and headache are among the symptoms. There may also be itching, raised spots on the skin, localised redness, a stabbing or shooting pain, tingling or burning sensation in or beneath the skin, or an upset stomach.

Impact of COVID-19 on the Global Herpes Zoster Treatment Market

In order to prevent cross-contamination, fewer procedures and patients have visited hospitals. This has a detrimental effect on the market for herpes zoster medications. Additionally, a reduction in staff was made to care for patients receiving herpes zoster therapy as a result of the transfer in medical personnel to treat COVID-19-infected individuals. As a result, non-elective procedures were delayed at several hospitals and healthcare institutes. The market for herpes zoster medications, however, is anticipated to gradually rebound after the epidemic.

Scope of the Report:

Market size available for years: 2019-2032

Base year considered: 2021

Forecast period: 2022-2032

Segments covered: By Route Of Administration, By Treatment Type, By Distribution Channel

Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered: Abbott Laboratory, Bausch Health, Camber Pharmaceuticals, Cipla Inc., Eli Lilly and Co., GlaxoSmithKline PLC, Merck, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Global Herpes Zoster Treatment Market Segmentation:

By Route Of Administration: Based on the Route Of Administration, Global Herpes Zoster Treatment Market is segmented as; Oral and Topical.

By Treatment Type: Based on the Treatment Type, Global Herpes Zoster Treatment Market is segmented as; Antiviral Medications, Anti-inflammatory Medications and Other.

By Distribution Channel: Based on the Distribution Channel, Global Herpes Zoster Treatment Market is segmented as; Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Provider.

By Region: In terms of revenue, North America led the world market for treating herpes zoster and is predicted to maintain that position. This is a result of the presence of important actors throughout the region and the accessibility of cutting-edge healthcare facilities with skilled medical personnel.

Product Code: HLCA2221

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Herpes Zoster Treatment Market, By Route Of Administration, 2019-2032 (USD Million)

6.1. Oral
6.2. Topical

7. Global Herpes Zoster Treatment Market, By Treatment Type, 2019-2032 (USD Million)

7.1. Antiviral Medication
7.2. Anti-inflammatory Medications
7.3. other

8. Global Herpes Zoster Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

8.1. Drug Stores & Retail Pharmacies
8.2. Hospital Pharmacies
8.3. Online Provider

9. Global Herpes Zoster Treatment Market, By Region, 2019-2032 (USD Million)

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 Germany
- 9.2.2 United Kingdom
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Rest of South America
9.5 Middle East & Africa
- 9.5.1 Kingdom of Saudi Arabia
- 9.5.2 United Arab Emirates
- 9.5.3 Rest of Middle East & Africa

10. Company Profiles

10.1 Abbott Laboratory
- 10.1.1 Company details
- 10.1.2 Financial outlook
- 10.1.3 Product summary
- 10.1.4 Recent developments
10.2 Bausch Health
- 10.2.1 Company details
- 10.2.2 Financial outlook
- 10.2.3 Product summary
- 10.2.4 Recent developments
10.3 Camber Pharmaceuticals
- 10.3.1 Company details
- 10.3.2 Financial outlook
- 10.3.3 Product summary
- 10.3.4 Recent developments
10.4 Cipla Inc.
- 10.4.1 Company details
- 10.4.2 Financial outlook
- 10.4.3 Product summary
- 10.4.4 Recent developments
10.5 Eli Lilly and Co.
- 10.5.1 Company details
- 10.5.2 Financial outlook
- 10.5.3 Product summary
- 10.5.4 Recent developments
10.6 GlaxoSmithKline PLC
- 10.6.1 Company details
- 10.6.2 Financial outlook
- 10.6.3 Product summary
- 10.6.4 Recent developments
10.7 Merck
- 10.7.1 Company details
- 10.7.2 Financial outlook
- 10.7.3 Product summary
- 10.7.4 Recent developments
10.8 Novaritis AG
- 10.8.1 Company details
- 10.8.2 Financial outlook
- 10.8.3 Product summary
- 10.8.4 Recent developments
10.9 GoodRx
- 10.9.1 Company details
- 10.9.2 Financial outlook
- 10.9.3 Product summary
- 10.9.4 Recent developments
10.10 Pfizer Inc.
- 10.10.1 Company details
- 10.10.2 Financial outlook
- 10.10.3 Product summary
- 10.10.4 Recent developments
10.11 Teva Pharmaceutical Industries Ltd.
- 10.11.1 Company details
- 10.11.2 Financial outlook
- 10.11.3 Product summary
- 10.11.4 Recent developments